Quality Control of Human Pluripotent Stem Cell-Derived Retinal
Pigment Epithelium Cells for Regenerative Therapy

a 2024

Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy

SOURALOVÁ, Tereza, Katarína ČIMBOROVÁ, Vendula PELKOVÁ, Aleš HAMPL, Irena KOUTNÁ et. al.

Basic information

Original name

Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy

Authors

SOURALOVÁ, Tereza, Katarína ČIMBOROVÁ, Vendula PELKOVÁ, Aleš HAMPL and Irena KOUTNÁ

Edition

XV. mezinárodní konferenci Bioimplantologie a regenerativní medicína, Lednice, 2024

Other information

Language

English

Type of outcome

Konferenční abstrakt

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

ISBN

978-80-01-07293-6

Abstract

V originále

Human retinal pigment epithelial (RPE) cells form a monolayer of polarized pigmented epithelial cells located between the blood vessels of the eye and the neural retina. The key function of RPE cells is the maintenance and protection of light-sensitive photoreceptors. Degeneration of RPE cells accompanies age-related eye diseases and can lead to the loss of vision. The rescue of the patient´s vision can be achieved by the replacement of the RPE cells. Therefore, we aim to differentiate human embryonal stem cells and human induced pluripotent stem cells into fully functional RPE cells that would be suitable for regenerative therapy. To ensure the RPE cells are not released for the treatment of the patient until the quality has been considered satisfactory, we designed a panel of quality control tests that characterize a) functionality: phagocytosis, specific cytokine secretion, b) morphology, c) identity and viability: marker detection by immunocytochemistry and flowcytometry, d) immunogenicity: lymphocyte-graft cell immune reaction, HLA expression of RPE cells. These tests are prepared for translation into advanced therapy medicinal product (ATMP) manufacture according to good manufacturing practice (GMP).

Links

LM2023049, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministry of Education, Youth and Sports of the CR

NU22-08-00629, research and development project

Name: Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk

Investor: Ministry of Health of the CR, Subprogram 1 - standard

Citovat

SOURALOVÁ, Tereza, Katarína ČIMBOROVÁ, Vendula PELKOVÁ, Aleš HAMPL and Irena KOUTNÁ. Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy. In XV. mezinárodní konferenci Bioimplantologie a regenerativní medicína, Lednice. 2024. ISBN 978-80-01-07293-6.

@proceedings{2397977,
   author = {Souralová, Tereza and Čimborová, Katarína and Pelková, Vendula and Hampl, Aleš and Koutná, Irena},
   booktitle = {XV. mezinárodní konferenci Bioimplantologie a regenerativní medicína, Lednice},
   language = {eng},
   isbn = {978-80-01-07293-6},
   title = {Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy},
   year = {2024}
}

TY  - CONF
ID  - 2397977
AU  - Souralová, Tereza - Čimborová, Katarína - Pelková, Vendula - Hampl, Aleš - Koutná, Irena
PY  - 2024
TI  - Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy
SN  - 9788001072936
N2  - Human retinal pigment epithelial (RPE) cells form a monolayer of polarized pigmented epithelial cells located between the blood vessels of the eye and the neural retina. The key function of RPE cells is the maintenance and protection of light-sensitive photoreceptors. Degeneration of RPE cells accompanies age-related eye diseases and can lead to the loss of vision. The rescue of the patient´s vision can be achieved by the replacement of the RPE cells. Therefore, we aim to differentiate human embryonal stem cells and human induced pluripotent stem cells into fully functional RPE cells that would be suitable for regenerative therapy. To ensure the RPE cells are not released for the treatment of the patient until the quality has been considered satisfactory, we designed a panel of quality control tests that characterize a) functionality: phagocytosis, specific cytokine secretion, b) morphology, c) identity and viability: marker detection by immunocytochemistry and flowcytometry, d) immunogenicity: lymphocyte-graft cell immune reaction, HLA expression of RPE cells. These tests are prepared for translation into advanced therapy medicinal product (ATMP) manufacture according to good manufacturing practice (GMP).
ER  -

SOURALOVÁ, Tereza, Katarína ČIMBOROVÁ, Vendula PELKOVÁ, Aleš HAMPL and Irena KOUTNÁ. Quality Control of Human Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cells for Regenerative Therapy. In \textit{XV. mezinárodní konferenci Bioimplantologie a regenerativní medicína, Lednice}. 2024. ISBN~978-80-01-07293-6.

Detailed Information on Publication Record